Ernexa Therapeutics Inc. · NASDAQ:ERNA

Ernexa Therapeutics — Investor Presentation (September 2026)

17 slides from Ernexa Therapeutics's investor presentation, September 2026

  1. Slide 1: Modulating the Immune System to Target Cancer Through Synthetic iMSC Therapies

    M o d u l a t i n g t h e I m m u n e S y s t e m t o Ta r g e t C a n c e r T h r o u g h Synt heti c In du ced -Mes en chym al Stro m al Cel l (i MS C) Ther apies e rne xa t x.c om Se p te mb er 20 26 Nasdaq : ERNA

  2. Slide 2: Safe Harbor Statement

    S a f e H a r b o r St a t e m e n t This presentation (this “Presentation”) and any oral statements made in connection with this Presentation are for informational purposes only and do not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, de

  3. Slide 3: Providing Hope: Our Mission & Vision

    Providing Hope Our Mission & Vision Transform the treatment of cancer by developing scalable, affordable, off-the-shelf cell therapies that restore hope. We envision a future where cell therapies powered by synthetic iMSCs can offer new options for patients with limited treatment paths.

  4. Slide 4: Ernexa Therapeutics: A Publicly Traded, Preclinical-Stage Company

    E r n e x a T h e r a p e u t i c s : A P u b l i c l y Tr a d e d , P r e c l i n i c a l - S t a g e C o m p a n y D e v e l o p i n g S y n t h e t i c i M S C T h e r a p i e s w i t h Ta n g i b l e M i l e s t o n e s (I ND Su bmi ssio n in Q4 2 02 6 ) IL7_IL15 Secreting iMSC Upcoming R&D for

  5. Slide 5: Pipeline Driving Next-Generation iMSC Therapies Across Solid Tumors

    P i p e l i n e D r i v i n g N e x t - G e n e r a t i on i M S C T h e r a p i e s A cr o s s S o l i d Tu m or s Advancing Towards First-in-Human (FIH) Study With Lead Program ERNA-101 by Q1 2027 Upcoming Building a differentiated Asset Indication Combinations Preclinical Phase 1 Phase 2 Mileston

  6. Slide 6: ERNA-101: New Category of Immunotherapy Overcoming Limitations of MSCs & Cytokines

    ERNA-101: New Categ or y of Immunotherapy that Over comes the Limitations of Bo th Natura lly O cc urring MSCs & C ytokine s > 20-fold ERNA-101 100% Cure Rate ERNA-101 C. DUAL MECHANISM OF T/NK CELLS ACTIVATION: enhanced cytokine secretion in ovarian tumor xenograft model Mechanism 1: Mechanism 2: (

  7. Slide 7: ERNA-101: Pro-Inflammatory Fusion Cytokines (IL7_IL15) Secreting iMSC for Allogeneic Therapy

    E RN A - 1 01 : P r o- In f la m ma to r y Fu si o n C y to k in es ( IL 7_I L 1 5) S ec r etin g i MS C f o r Al lo gen ei c T h er a py

  8. Slide 8: ERNA-101: Pro-Inflammatory Fusion Cytokines (IL7_IL15) Secreting iMSC

    E R N A - 1 0 1 : P r o - I n f l a m m a t o r y F u s i o n C y to k i n e s ( I L 7 _ I L 1 5 ) Se c re tin g i MSC f or A ll oge ne i c Th e ra py In combination with anti PD-1 antibody demonstrated 100% survival and complete tumor clearance in ovarian cancer models; advancing towards phase 1 tr

  9. Slide 9: A Significant Opportunity in Platinum-Resistant Ovarian Cancer (PROC)

    A S i g n i f i ca n t O p p o r t u n i t y i n P l a t i n u m - Re s i s t a n t O v a r i a n C a n c e r ( P R O C ) PROC is a subset of recurrent ovarian cancer, defined by disease progression within six months after completing platinum-based Outcomes for patients with PROC are poor, highlight

  10. Slide 10: Mechanism of Action of ERNA-101: Trojan Horse for Cancer

    M e c h a n i s m o f A c t i o n o f E R N A - 1 0 1 : L e v e r a g i n g t h e I n t r i n s i c Tu m o r - H o m i n g A b i l i t y o f M S C s t o C r e a t e a Tr o j a n H o r s e f o r C a n c e r . Cold Tumor . Hot Tumor • ERNA-101 consists of iMSCs engineered to secrete a novel immune-enh

  11. Slide 11: ERNA-101 Treatment Leads to Substantial Accumulation of IL7_IL15 and T Cell Infiltration

    E R N A - 1 0 1 Tr e a t m e n t L e a d s t o S u b s t a n t i a l A c c u m u l a t i o n o f I L 7 _ I L 1 5 & Si gni fi can t Incre ase i n C D4 an d C D 8 T C e ll Inf ilt ra t ion in to t he T ME • Ovarian tumor-bearing mice were treated with PBS (no treatment control), iMSC-GFP (control iMSC

  12. Slide 12: Breakthrough Preclinical Result: ERNA-101 + Anti-PD-1 Ab Exhibited 100% Survival

    B r e a k t h r o u g h P r e c l i n i c a l Re s u l t : E R N A - 1 0 1 + An t i P D - 1 a b E x h i b i t ed 1 0 0 % S u r v i v a l & C o m p l e t e Tu m o r C l e a r a n c e i n O v a r i a n C a n c e r M o d e l Combination of ERNA-101 with Anti-PD1 Antibody Leads to Complete Regressions a

  13. Slide 13: Planned First-in-Human Phase 1 Open Label, Single Arm Study of ERNA-101

    Plan n ed Firs t-In-H uma n Ph as e 1 Ope n Labe l, Sin gle Arm S t u d y of E R N A - 1 0 1 ± Pe m b r o l i z u m a b a n d B e v a ci z u m a b * ERNA-101 (IP) Monotherapy Dose-Escalation - Q3W SCREENING Follow Up Assessment Baseline Cycle 1 Cycle 2 Cycle 3 Cycle 4 PART 1 (N =12) 1 2 3 4 5 6 7 8

  14. Slide 14: Trading Snapshot, Development Plan, Investment Summary & Concluding Remarks

    Tr a din g S n a p sh ot , D evel o pm en t P la n , In ves tm en t S u mm a r y & Co n c lu din g Rem a rk s

  15. Slide 15: Nasdaq: ERNA Trading Snapshot

    N a s d a q : E R N A : Tr a d i n g S n a p s h o t Sufficient Capital to Fund Development Through Multiple Value Driving Milestones, Including the Launch of the First-in-Human Study Key Highlights Cash Market Cap Avg. Volume Shares ~$8.0 MM ~$6.4 MM ~477 K 1.6 MM As of August 6, 2026 As of Sep 9,

  16. Slide 16: Ernexa's Development Plan for Next Months: Near Term Tangible Milestones

    E r n e x a’s D ev el o p m e n t P l an f o r N ex t 2 4 M o n th s : S e v e r a l N e a r Te r m Ta n g i b l e M i l e s t o n e s w i t h E R N A - 1 0 1 E n t e r i n g I n t o Cli ni c al P ro gram in 2027 an d Ne xt -Gen eratio n Asset A dvan cem en t Q3-2026 Q4-2026 Q1-2027 Q2-2027 Q3-2027

  17. Slide 17: We Are Driving Towards Meaningful Outcomes; More Time for the Moments That Matter

    We A r e D r i v i n g To w a r d s M e a n i n g f u l O u tc o m e s ; More Time for the Mome nts Th a t M atte r • Despite decades of progress, outcomes for platinum- resistant ovarian cancer remain devastating HOPE • Families carry the emotional burden We aim to change what it means to live with

Ernexa Therapeutics — Investor Presentation (September 2026) on 6ix